利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.023 秒)

    Herpes simplex virus glycoprotein D variants
    1.
    发明授权
    Herpes simplex virus glycoprotein D variants 失效
    单纯疱疹病毒糖蛋白D变体

    公开(公告)号：US5654174A

    公开(公告)日：1997-08-05

    申请号：US499568

    申请日：1995-07-07

    申请人： Gary H. Cohen ,  Roselyn J. Eisenberg ,  Anthony Nicola

    发明人： Gary H. Cohen ,  Roselyn J. Eisenberg ,  Anthony Nicola

    IPC分类号： A61K38/00 ,  A61K39/00 ,  C07K14/035 ,  C12N15/38 ,  C12P21/02 ,  C12N5/10

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C12N2710/14143 ,  C12N2710/16622 ,  Y10S930/224

    摘要： The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues. When expressed in Sf9 cells, cleavage of the melittin signal peptide results in the presence of aspartate and proline residues at the amino terminus of the variant molecule. The amino acid sequence of gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 2 and the preferred DNA sequence encoding gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 1. Administration of gD variant molecules of the invention to mammalian subjects, especially humans, for the purpose of preventing HSV infection and/or ameliorating pathological sequelae of HSV infection is specifically contemplated.

    摘要翻译： 本发明提供能够预防1型和/或2型单纯疱疹病毒感染细胞的变体HSV-1糖蛋白D和HSV-2糖蛋白D分子。还提供了编码变体gD分子的新型纯化和分离的多核苷酸。 HSV gD-1和gD-2区IV变体或其片段是本发明具体考虑的。 目前优选的变体分子gD-1（DELTA 290-299t）是在融合蛋白的Sf9细胞中重组表达的产物，包括蜜蜂蜂毒素和巴顿菌株HSV-1 gD的信号肽，其中（1）Patton菌株氨基酸 成熟gD-1蛋白的残基290至299已被氨基酸残基精氨酸，赖氨酸，异亮氨酸和苯丙氨酸替代，（2）Patton菌株氨基酸残基308至369被五个组氨酸残基取代。 当在Sf9细胞中表达时，蜂毒肽信号肽的切割导致在变体分子的氨基末端存在天冬氨酸和脯氨酸残基。 gD-1（DELTA 290-299t）的氨基酸序列示于SEQ ID NO：2中，编码gD-1（DELTA 290-299t）的优选DNA序列列于SEQ ID NO：1中。 具体考虑本发明的gD变体分子对于哺乳动物受试者，特别是人来说是为了预防HSV感染和/或改善HSV感染的病理后遗症的目的。

    Soluble herpesvirus glycoprotein complex vaccine
    3.
    发明授权
    Soluble herpesvirus glycoprotein complex vaccine 失效
    可溶性疱疹病毒糖蛋白复合疫苗

    公开(公告)号：US06541459B1

    公开(公告)日：2003-04-01

    申请号：US09658056

    申请日：2000-09-08

    申请人： Gary H. Cohen ,  Roselyn J. Eisenberg ,  Tao Peng ,  Gary Dubin

    发明人： Gary H. Cohen ,  Roselyn J. Eisenberg ,  Tao Peng ,  Gary Dubin

    IPC分类号： A01N4304

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  C12N2710/16622

    摘要： The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.

    摘要翻译： 本发明涉及包含单纯疱疹病毒糖蛋白H-糖蛋白L复合物的单纯疱疹病毒疫苗。 本发明还涉及包含编码单纯疱疹病毒糖蛋白H-糖蛋白L复合物的DNA的疫苗。 还包括特异性结合单纯疱疹病毒糖蛋白H-糖蛋白L复合物的抗体和编码它的DNA。

    Materials and methods for herpes simplex virus vaccination
    9.
    发明授权
    Materials and methods for herpes simplex virus vaccination 失效
    单纯疱疹病毒疫苗接种的材料和方法

    公开(公告)号：US4709011A

    公开(公告)日：1987-11-24

    申请号：US734063

    申请日：1985-05-15

    申请人： Gary H. Cohen ,  Roselyn J. Eisenberg

    发明人： Gary H. Cohen ,  Roselyn J. Eisenberg

    IPC分类号： A61K39/00 ,  C07K14/035 ,  G01N33/569 ,  C07K7/06 ,  A61K39/12 ,  C07K7/08

    CPC分类号： G01N33/56994 ,  C07K14/005 ,  G01N33/569 ,  A61K39/00 ,  C12N2710/16622 ,  Y10S930/224

    摘要： Disclosed are immunologically active preparations of Herpes simplex virus envelope glycoproteins, gD-1 and gD-2. Preferably purified through use of a monoclonal anti-gD antibody immunodsorbent, gD-1 and gD-2 preparations are incorporated in vaccines useful in generating immunological responses protective against Herpes simplex virus disease states. Disclosed also is the preparation and use in vaccination procedures of synthetic polypeptides comprising amino acid squences which are: (1) substantially common to both gD-1 and gD-2; (2) cumulatively hydrophilic in nature; (3) specifically immunoreactive with a type common, monoclonal anti-gD antibody of Group VII classification. Vaccines incorporating the synthetic polypeptides give rise to protective immunological responses, e.g., they protect mice against Herpes simplex.

    摘要翻译： 公开了单纯疱疹病毒包膜糖蛋白gD-1和gD-2的免疫活性制剂。 优选通过使用单克隆抗gD抗体免疫吸附剂纯化，gD-1和gD-2制剂掺入可用于产生针对单纯疱疹病毒病状态的免疫应答的疫苗中。 还公开了包含氨基酸序列的合成多肽的疫苗接种程序的制备和应用，其为：（1）gD-1和gD-2基本上共同的; （2）性质上累积亲水; （3）与第VII类分类的常见的单克隆抗gD抗体特异性免疫反应。 掺入合成多肽的疫苗产生保护性免疫应答，例如它们保护小鼠免于单纯疱疹。